BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld
Home
» Merrimack Pharmaceuticals Aims to Raise $100M in IPO
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Merrimack Pharmaceuticals Aims to Raise $100M in IPO
March 30, 2012
By
Catherine Shaffer
No Comments
Merrimack Pharmaceuticals Inc., which has initiated six new clinical trials since August 2011, priced an initial public offering (IPO) of 14.3 million shares of common stock at $7 per share, for a total anticipated raise of about $100 million.
BioWorld